Lilly declined to comment on its legal strategy, with a spokesperson stating that retatrutide qualifies as a biologic under the governing statute. The FDA said it does not comment on pending litigation, and HHS did not respond to a request for comment as of press time
The FDA Adverse Event Reporting System now shows a reporting odds ratio of 2.46 for alopecia with semaglutide, meaning hair loss reports are nearly two and a half times higher than expected
Clear solution indicates proper reconstitution
GLP-1 receptors modulate incretin signaling and gastric motility
If this is your first injection, your dose will be 0.25mg
This "research use only" designation carries specific implications: Researchers are expected to use the material in legitimate research contexts, whether academic studies, independent investigation, or institutional research programs